Cingulate Inc
CING
Company Profile
Business description
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
Contact
1901 West 47th Place
KansasKS66205
USAT: +1 913 942-2300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Finding value in some of the ASX’s worst recent performers.
stocks
Rethinking the way we invest in Aussie tech
Investing in Tech companies has many caveats from traditional investing. Let’s dive into how you can gauge the true profitability of a tech company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,884.70 | 38.30 | -0.43% |
| CAC 40 | 8,122.71 | 23.24 | 0.29% |
| DAX 40 | 23,836.79 | 68.83 | 0.29% |
| Dow JONES (US) | 47,716.42 | 289.30 | 0.61% |
| FTSE 100 | 9,720.51 | 26.58 | 0.27% |
| HKSE | 25,967.11 | 108.22 | 0.42% |
| NASDAQ | 23,365.69 | 151.00 | 0.65% |
| Nikkei 225 | 49,465.73 | 788.18 | -1.57% |
| NZX 50 Index | 13,446.36 | 42.79 | -0.32% |
| S&P 500 | 6,849.09 | 36.48 | 0.54% |
| S&P/ASX 200 | 8,585.10 | 29.00 | -0.34% |
| SSE Composite Index | 3,893.78 | 5.19 | 0.13% |